Correlation between clinical features and circulating levels of soluble intercellular adhesion molecule-1 in Hodgkin's disease

[1]  M. Chilosi,et al.  Circulating soluble ICAM-1 in patients with Hodgkin's disease. , 1994, Immunology today (Amsterdam. Regular ed.).

[2]  M. Chilosi,et al.  Circulating soluble adhesion molecules: more observations on ICAM-1 in patients with Hodgkin's disease , 1994 .

[3]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[4]  F. Herrmann,et al.  Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. , 1993, Leukemia.

[5]  C. Pui,et al.  Serum intercellular adhesion molecule-1 in childhood malignancy. , 1993, Blood.

[6]  M. Chilosi,et al.  ICAM‐1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease , 1993, British journal of haematology.

[7]  R. Rothlein,et al.  A form of circulating ICAM-1 in human serum. , 1991, Journal of immunology.

[8]  H. Müller-Hermelink,et al.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. , 1991, The American journal of pathology.

[9]  R. Rothlein,et al.  Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. , 1991, Cancer research.

[10]  M. Makgoba,et al.  Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders , 1991, The Lancet.

[11]  M. Diamond,et al.  ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18) , 1990, The Journal of cell biology.

[12]  Longo Dl.  The use of chemotherapy in the treatment of Hodgkin's disease. , 1990 .

[13]  R. Hoppe.  Radiation therapy in the management of Hodgkin's disease. , 1990, Seminars in oncology.

[14]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[15]  S. Uccini,et al.  Cytokine Production (IL-1α, IL-1β, and TNFα) and Endothelial Cell Activation (ELAM-1 and HLA-DR) in Reactive Lymphadenitis, Hodgkin's Disease, and in Non-Hodgkin's Lymphomas: An Immunocytochemical Study , 1990 .

[16]  T. Waldmann,et al.  Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Emmrich,et al.  Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients , 1990, Scandinavian journal of immunology.

[18]  R. Rothlein,et al.  Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. , 1990, Science.

[19]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Rothlein,et al.  Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. , 1988, Journal of immunology.

[21]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[22]  M. Chilosi,et al.  THE SOLUBLE INTERLEUKIN‐2 RECEPTOR IN HAEMATOLOGICAL DISORDERS , 1987, British journal of haematology.

[23]  G. Janossy,et al.  Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. , 1984, British Journal of Cancer.